On November 27, the Maryland Prescription Drug Affordability Board heard comments on its proposed regulations for selecting drugs for cost review and the study process.  Click here to review several public comments received and details of the regulations.  Maryland Matters reported that two rules were finalized during the meeting, including a list of definitions and procedure for public comments, as well as an outline of the cost review process that could result in price-lowering efforts.